Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches.

Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death.

Spastin MIT Domain Disease-Associated Mutations Disrupt Lysosomal Function.

An Emerging Human Parechovirus Type 5 Causing Sepsis-Like Illness in Infants in Australia.

Improving patient outcomes with neighbourhood care: the Coldstream experience.

Global Emergency Medicine: A Review of the Literature from 2018.

Interventions addressing men, masculinities and gender equality in sexual and reproductive health and rights: an evidence and gap map and systematic review of reviews.

Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs).

The American Society of Hematology (ASH) Medical Educators Institute: a Pilot Faculty Development Project for Hematology Educators.

Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs).

Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs).

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Is palliative care cost-effective in low-income and middle-income countries? A mixed-methods systematic review.